Previous Article | Next Article 
Journal of Virology, December 2001, p. 11621-11629, Vol. 75, No. 23
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.23.11621-11629.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Porcine Encephalomyocarditis Virus Persists in Pig
Myocardium and Infects Human Myocardial Cells
Laurie A.
Brewer,1
Humphrey C. M.
Lwamba,1
Michael P.
Murtaugh,1
Ann
C.
Palmenberg,2
Corrie
Brown,3 and
M. Kariuki
Njenga1,*
Department of Veterinary Pathobiology,
University of Minnesota, St. Paul, Minnesota
551081; Department of Biochemistry,
University of Wisconsin, Madison, Wisconsin
537062; and Department of Pathology,
College of Veterinary Medicine, University of Georgia, Athens, Georgia
306023
Received 11 June 2001/Accepted 28 August 2001
 |
ABSTRACT |
Recent advances toward using pig tissues in human transplantation
have made it necessary to determine the risk of transmitting zoonotic
viruses from pigs to humans or vice versa. We investigated the
suitability of the porcine encephalomyocarditis virus (EMCV) model for
such studies by determining its ability to persist in pigs, escape
detection by routine serological methods, and infect human cells.
Intraperitoneal inoculation of 5-week-old pigs with EMCV-30, a strain
isolated from commercial pigs, resulted in acute cellular degeneration,
infiltration of lymphocytes, and apoptosis in myocardium in 13 of 15 (86.7%) pigs during the acute phase of disease (3 to 21 days
postinfection), followed by less-severe lymphocytic infiltration and
apoptosis in 5 of 10 (50%) pigs during the chronic phase of the
disease (day 45 to 90 postinfection). In the brain, lymphocytic
infiltration, neuronal degeneration, and gliosis were observed in 26 to
33% of pigs in the acute phase of disease whereas perivascular cuffing
was the predominant feature during chronic disease. EMCV antigens and
RNA were demonstrated in the myocardium and brain during the chronic
phase of disease. Analysis of 100 commercial pigs that were negative
for EMCV antibodies identified two pig hearts positive for EMCV RNA.
Porcine EMCV productively infected primary human cardiomyocytes as
demonstrated by immunostaining using a monoclonal antibody specific for
EMCV RNA polymerase, which is expressed only in productively infected cells, and by a one-step growth curve that showed production of 100 to
1,000 PFU of virus per cell within 6 h. The findings that porcine
EMCV can persist in pig myocardium and can infect human myocardial
cells make it an important infectious agent to screen for in
pig-to-human cardiac transplants and a good model for xenozoonosis.
 |
INTRODUCTION |
Encephalomyocarditis virus
(EMCV) is a widely distributed
picornavirus belonging to the Cardiovirus genus. The
picornavirus infects many animal species including pigs
(15), rodents (41), cattle,
(35), elephants (11), raccoons
(43), marsupials (30), and primates such as
baboons, monkeys, chimpanzees, and humans (3, 14, 17, 30, 38,
41). Rats and mice are the natural hosts of the virus, passing
the virus to other species through fecal-oral transmission. In rodents
EMCV causes lesions in the heart, pancreas, central nervous system, and
testes (4, 28). Pigs are the most commonly and severely
infected domestic animals, as EMCV is endemic in many pig populations
(2, 9). The virus causes acute myocarditis and sudden
death in preweaned pigs, whereas transplacental infection of sows
causes fetal mummification, abortion, stillbirth, and neonatal death
(15). Infections in older pigs are asymptomatic. Even
though no detailed pathogenetic studies have been performed to
determine the porcine cells supporting EMCV replication and possible
persistence, the heart, liver, and kidney have been shown to have
higher EMCV titers than blood, suggesting that EMCV replicates in these
organs (5).
Studies indicate that EMCV can cause interspecies infections, making it
an important zoonotic agent (14, 18, 30, 31). For example,
EMCV strains isolated from different species are antigenically similar,
and isolates that have caused myocarditis and pancreatitis in pigs have
been associated with rodent outbreaks (18, 31, 39). The
few documented cases of EMCV infection in humans have been associated
with fever, neck stiffness, lethargy, delirium, headaches, and vomiting
(24). In Germany, strains of the virus have been isolated
from children suffering from meningitis and encephalitis, although a
causal relationship between EMCV and the symptoms was not demonstrated
(10). In Australia, cases of human EMCV infection have
been reported in New South Wales, an area with a high incidence of the
pig disease (17). Although an EMCV outbreak in a United
States zoo involving multiple animal species did not result in illness
to humans, a zoo attendant who cared for EMCV-infected primates
demonstrated an antiviral antibody titer of 1:1,280 (41).
Renewed interest in pig-to-human zoonotic viruses has arisen from
advances in xenotransplantation as a means of overcoming the acute
shortage of transplantation tissues and organs for humans. Porcine
cells, tissues, and organs are the primary animal tissues being
considered for human transplantation because of similar anatomical and
physiological features in humans and pigs, ready availability of the
species, and relative ease of breeding pigs. For example, porcine
neuronal cells, hepatocytes, and pancreatic islet cells are in various
stages of trials for transplantation into humans, and the results are
encouraging (23, 27, 29, 32, 37). In patients with
Parkinson's disease, a neurodegenerative disorder characterized by
loss of neurons in the substantia nigra and a corresponding decrease in
dopamine levels within the striatum, intracerebrally transplanted
dopamine-producing pig neural cells have survived for as long as 7 months and formed extensive axonal connections with the human host
neurons (23, 29). In diabetes mellitus, a disease for
which islet transplants have the potential to become an effective
treatment, transplantation of fetal porcine islet cell clusters under
the kidney capsule of cynomolgus monkeys resulted in delayed rejection,
holding promise that use of xenogeneic islet tissues in humans may be
attempted soon (32, 34).
A major concern in xenotransplantation is that disruption of anatomical
barriers resulting in intimate contact between recipient and xenograft,
combined with the routine immunosuppression of recipients, may
facilitate interspecies transmission of xenogenic infectious agents to
a substantially greater extent than would normal contact between humans
and animals (13). To address this concern, researchers are
investigating the risk posed by porcine viruses such as swine influenza
virus, parainfluenza virus 1, EMCV, and retroviruses by
determining whether the viruses can establish persistent
infection (13). Cardioviruses can establish persistence
via mechanisms that are not fully understood. For example, Theiler's
murine encephalomyelitis virus (TMEV) can persist in the spinal cord
white matter of susceptible mice for as long as 2.5 years, causing
chronic myelin destruction (22). EMCV RNA has been
detected in the myocardia of mice 90 days after the virus-mediated
myocytolytic stage of the disease, and at 1 month after birth
infectious virus can be recovered from piglets infected in utero
(19, 21, 40). These findings suggest that EMCV can persist
for some period after the acute disease. Detection of viral antibodies
by virus neutralization or enzyme-linked immunosorbent assay (ELISA)
and virus isolation are the routine tests used for the diagnosis of
EMCV infection. We investigated the suitability of EMCV as a
xenozoonosis model by determining whether the virus persists in pig
tissues or infects human cells and by determining the potential for
persistent EMCV to escape detection by routine screening methods. In
situ hybridization, reverse transcription-PCR (RT-PCR), and
immunohistochemistry were used to determine the persistence of EMCV in
pig tissues, and morphometric analysis was used to characterize
associated pathologic changes. The potential for seronegative pigs to
harbor EMCV and the ability of porcine EMCV to infect human cells were determined.
 |
MATERIALS AND METHODS |
Virus.
The MN-30 strain of EMCV (EMCV-30), isolated from
naturally infected pigs in Minnesota in 1987 and kindly provided by
HanSoo Joo of the Department of Veterinary Pathobiology, University of Minnesota, was used in all experiments (16). The virus was
propagated in HeLa cells. EMCV purification for ELISA was performed as
described previously for TMEV (26). Briefly, supernatant
from infected HeLa cells was clarified by adding IGEPAL CA-630 (Sigma)
and centrifuging at 10,000 × g for 20 min. Sodium
dodecyl sulfate (0.5%) was added to the lysate, and the solution was
underlaid with 30% (wt/wt) sucrose and centrifuged at
77,000 × g for 3 h at 20°C. The pelleted virus
was overlaid on a cesium chloride gradient (density, 1.2 to 1.4 g/ml), and centrifuged at 77,000 × g overnight
at 5°C. The band containing purified virus was dialyzed in
phosphate-buffered saline and stored at
80°C. Viral stocks were
titered by plaque assay on HeLa cells and stored at
80°C.
Experimental infection of pigs and sample collection.
Twenty-five 5-week old pigs were obtained from an EMCV-free swine herd
(Midwest Research Swine, Gibbon, Minn.) and placed in negative-pressure
isolation units at the University of Minnesota animal facilities. ELISA
confirmed the pigs to be negative for EMCV antibodies before infection.
Animals were intraperitoneally inoculated with 2.9 × 108 (PFU) of EMCV-30 in a 1-ml volume. Handling of animals,
including feeding and euthanasia, was in conformity with the National
Institutes of Health and University of Minnesota institutional animal
care guidelines. Four to six pigs were euthanized at days 7, 21, 45, and 90 postinfection (p.i.) using pentobarbital sodium. Tissues from
the brain, heart, kidney, liver, spleen, skeletal muscle, pancreas, and
mesenteric lymph node tissues were collected for RNA isolation,
histopathology, and immunohistochemistry. Tissues for RNA isolation and
cryosectioning were snap-frozen in liquid nitrogen, whereas tissues for
histopathology and in situ hybridization were fixed in 10% neutral
buffered formalin and embedded in paraffin. Paraffin-embedded sections
were cut at a 4 µm thickness and stained with hematoxylin and eosin
for histopathologic analysis. Sera were collected from pigs before
inoculation and at sacrifice for ELISA and virus neutralization.
Sera and heart tissues from commercial pigs.
A total of 100 hearts (10 samples per herd) were obtained from slaughter pigs
originating from a central Minnesota pig farm and demonstrated to be
EMCV free by virus neutralization. Heart tissues were analyzed for EMCV
RNA by nested RT-PCR. Serum samples were also collected from these pigs
and were analyzed for EMCV antibodies by virus neutralization and ELISA.
Nested RT-PCR.
Pig tissues collected at days 7, 21, 45, and
90 p.i., and heart tissues obtained from commercial pigs, were
analyzed for EMCV RNA by nested RT-PCR. One gram of brain, heart,
liver, kidney, spleen, or skeletal muscle was homogenized in TRIzol
(Life Technologies, Gaithersburg, Md.), followed by chloroform
extraction of total RNA. Five micrograms of total RNA was reverse
transcribed using an oligo(dT) primer and the Superscript II reverse
transcription kit (Life Technologies) before the outer and nesting PCRs
using primer pairs specific for the VP1 or VP2 genes (6)
(GenBank accession no. M81861) were performed. The VP1 primers used for
the outer PCR were CGAACTCAGTGATACTGACCCCTG for the 5'
primer and CCAGCTCTCGGGGTCATATCAATC for the 3' primer,
whereas those for the nesting reaction were
GTCTGACAGAAATTTGGGGCAATG for the 5' and
GTCAGGCTTTGTGCCAGCAAAGAAC for the 3' primer. The VP2 primers for the outer PCR were CAGTGGGCCGTCTTGTCGGTTATG for the 5'
and CCTCAAGATCCACTGTGGTGTTAG for the 3' end, whereas nesting
primers were GGCATCATGTGCTGACACTGCTTCAG for the 5' and
CCACTGCCAGAAGTTCTGATGGTC for the 3' end. All primers are
listed in 5'-to-3' orientation. The outer PCR was performed on 1 µl
of the template cDNA by adding 0.2 mM deoxynucleoside triphosphates, 2 mM magnesium chloride, 10 pmol of each primer, and 1 U of
Taq polymerase (Life Technologies). For the nested PCR, 2.5 µl of the first-round PCR reaction mixture was used. PCR products
were analyzed using agarose gel electrophoresis.
In situ hybridization.
To detect the presence of viral
genome in pig tissues, in situ hybridization was performed using a
309-bp VP2-specific probe as described previously for TMEV
(25). Briefly, a VP2 cDNA was subcloned from a full-length
EMCV cDNA (pEC9 clone) into plasmid pUC 18 using BamHI and
EcoRI restriction sites, and the cDNA probe was prepared by
digesting the VP2 plasmid with NcoI and KpnI
restriction enzymes (12). The probe was labeled with
[35S]dATP using the Random Primers DNA Labeling System
(Life Technologies) and was purified using G-50 Sephadex Quick Spin
columns (Roche, Indianapolis, Ind.). To prepare tissue samples,
paraffin-embedded sections were deparaffinized using xylene whereas
cryostat sections were fixed in 0.5% paraformaldehyde-0.5%
glutaraldehyde-0.02 M disodium phosphate-0.08 M sodium
phosphate-0.002% calcium chloride-1% dimethyl sulfoxide-1.6%
glucose. Sections were digested with 10 µg of proteinase K/ml in
phosphate-buffered saline for 30 min at 37°C and then treated with
0.1 M triethanolamine containing acetic anhydride. The sections were
prehybridized in a buffer containing deionized formamide, Denhardt's
solution, sodium chloride, salmon sperm DNA, yeast total RNA, and yeast
tRNA for 4 h at room temperature before hybridization with
35S-labeled 309-bp VP2 probe. Hybridization was performed
overnight at 37°C, followed by extensive washes in reducing buffer at
55°C. Air-dried slides were immersed in an NTB2 film emulsion
(Eastman Kodak Co., Rochester, N.Y.) and exposed at 4°C for 5 days.
Histopathologic analysis.
Blinded histologic analysis was
performed on the hearts, brains, livers, kidneys, spleens, skeletal
muscles, pancreases, and mesenteric lymph nodes of pigs infected with
EMCV for 7, 21, 45, and 90 days. Each section was given a score between
0 and 4 based on specific criteria. Sections with no pathologic changes
were given a score of 0, and sections demonstrating only rare foci of
degeneration or inflammatory cell infiltrate were given a score of 1. Sections with multiple foci of moderate cellular degeneration, increased inflammatory cell infiltrate, and moderate fibroblast infiltration were given a score of 2, whereas those with severe degeneration and inflammatory infiltration but no necrosis were given a
score of 3. Tissues with areas of acute degeneration, necrosis, severe
inflammatory cell infiltrate, mineralization, and extensive fibroplasia
were given a score of 4.
Immunohistochemistry.
To detect the presence of replicating
virus in pig tissues and primary human cells, a mouse monoclonal
antibody specific for the EMCV RNA polymerase (3D protein) was used
(7). Sections of frozen heart tissue (thickness, 6 µm)
were fixed in cold acetone for 20 min and blocked in 10% normal goat
serum for 30 min. An anti-polymerase antibody was added, followed by
peroxidase-conjugated goat anti-mouse immunoglobulin G (IgG) (Roche).
Addition of 3,3'-diaminobenzidine substrate (Vector Laboratories,
Burlingame, Calif.) for 10 min localized the EMCV antigens. Slides were
counterstained with Mayer's hematoxylin and were examined by light microscopy.
Detection of apoptosis.
Cells undergoing apoptosis were
identified using a commercial kit according to the manufacturer's
instructions (Roche Diagnostics GmbH, Mannheim, Germany). Frozen heart
sections were fixed in 4% paraformaldehyde before quenching with 3%
H2O2 in methanol for 10 min. Terminal
deoxynucleotidyl transferase (derived from calf thymus) was added to
incorporate the fluorescein-labeled nucleotides at DNA strand breaks,
followed by horseradish peroxidase-labeled sheep anti-fluorescein Fab
fragment to detect the incorporations. Apoptotic cells were localized
by addition of 3,3'-diaminobenzidine substrate and brown color
development. Slides were lightly counterstained with hematoxylin and
were analyzed by light microscopy.
Virus neutralization.
Sera were serially diluted from 1:8 to
1:2,048 in microtiter plates (dilutions run in triplicate); then 1,000 50% tissue culture infective doses of EMCV-30 was added to each
dilution and incubated at 37°C for 1 h. Baby hamster kidney
cells were added to each well, and the neutralizing antibody titer was
read as the highest serum dilution at which a confluent cell monolayer
was observed. A neutralizing serum titer of 1:16 dilution or higher was
considered definitive for EMCV infection, with a sensitivity of 93.9%
and specificity of 100% (42).
Anti-EMCV IgG ELISA.
EMCV-specific IgGs were detected by
ELISA using purified EMCV as an antigen as described previously for
TMEV (26). Plates were coated with UV-inactivated purified
EMCV at a concentration of 0.5 µg/well in 0.1 M sodium carbonate
buffer (pH 9.5) and blocked with 1% bovine serum albumin. Fourfold
dilutions of serum from 1:40 to 1:128,000 made in 0.2% bovine serum
albumin were added to the wells, followed by biotinylated goat
anti-swine IgG (Kirkegaard and Perry, Gaithersburg, Md.). Each serum
dilution was run in triplicate. Virus-specific IgG binding was detected
using a 1:2,000 dilution of alkaline phosphatase-conjugated
streptavidin (Jackson ImmunoResearch, West Grove, Pa.) followed by
substrate development with p-nitrophenyl phosphate (Sigma
Diagnostics) in buffer containing 0.1 M carbonate and 1 mM magnesium
chloride at pH 9.5. Color intensity was read at 405 nm using an ELISA
plate reader (Molecular Devices, Sunnyvale, Calif.).
Human cell culture and infection.
To determine the
susceptibility of human cells to porcine EMCV, primary human cells were
obtained from various sources and inoculated with EMCV-30.
Cryopreserved human renal epithelial cells, fetal aortic endothelial
cells, cardiomyocytes, bone marrow progenitor mononuclear cells, and
peripheral blood mononuclear cells were obtained from Clonetics, a
subsidiary of BioWhittaker (Walkersville, Md.). The human
cardiomyocytes were isolated from normal human hearts and confirmed to
be positive for MF-20 myosin (>95% of cells) and sarcometric actin
(95 to 100% of cells) but negative for smooth muscle
-actin. All
cell types from Clonetics were cultured in the media and under the
conditions recommended by the manufacturer. Primary human hepatocytes
derived from liver biopsies were generously provided by Stephen Strom,
University of Pittsburg. Human neuroblastoma cells were obtained from
the American Type Culture Collection (CHP-212) and cultured in a 1:1 mixture of minimum essential medium and Ham's F-12 medium with 10%
fetal bovine serum. All cell types were directly inoculated with
EMCV-30 or passaged once before inoculation. Virus inoculation was
performed in T-75 flasks with 3 to 5 PFU of EMCV-30 per cell for 7 h at 37°C. After infection, cells were mounted onto glass slides and
used for in situ hybridization or immunohistochemistry.
 |
RESULTS |
Clinical and histopathologic changes are associated with primary
myocardial infection.
Of the 25 pigs infected with EMCV, 4 (16%)
died at day 3 p.i. from acute myocarditis. These pigs showed
extensive lysis of sarcoplasm, cellular degeneration, and early
mineralization in the myocardium. Congestion of the lungs and liver
were also noted, but no abnormalities in the brain or any other organs
were detected at day 3 p.i. The other 21 pigs (84%) did not
develop any clinical illness throughout the 90-day experimental period.
At days 7, 21, 45, and 90 p.i., heart, brain, spleen, liver,
skeletal muscle, kidney, pancreas, and mesenteric lymph node tissues
were collected and processed for histopathologic analysis. The most
severely affected organs were the heart and brain. During the acute
phase of the disease (days 3 to 21 p.i.), the most common gross
abnormalities were multiple foci of pale myocardial lesions, observed
in all pigs (n = 15) sacrificed during this period.
Histologically, pigs sacrificed at 7 and 21 days p.i. showed severe
myocardial lesions including multiple foci of degeneration and necrosis
with lysis of sarcoplasm and early
mineralization (Fig. 1A and
2). In some cases, a lymphocytic
inflammatory infiltrate was present (Fig. 1). In the chronic phase of
the disease (days 45 and 90 p.i.), multiple discrete nodules of
myocardial mineralization were observed grossly in 3 of 10 (30%) pigs.
Approximately 63% of the pigs sacrificed at days 45 and 90 p.i.
showed discrete foci of apoptotic cells and inflammatory cell
infiltration in the myocardium (Fig. 1C and 3), suggesting an active
infectious and/or inflammatory process in the chronic phase of the
disease. Compared to heart tissues from acutely infected pigs,
myocardial tissues from chronically infected pigs had smaller and fewer
areas of inflammation and discrete foci of fibrosis and repair. Cells
undergoing apoptosis were demonstrated in myocardial tissues during
both the acute and chronic phases of the disease; however, apoptotic
cells were most numerous at day 7 and were fewer but consistently
present at days 45 and 90 p.i. (Fig.
3).

View larger version (153K):
[in this window]
[in a new window]
|
FIG. 1.
EMCV-induced pathologic changes in the heart and brain.
Five-week-old pigs were intraperitoneally inoculated with 2.9 × 108 PFU of EMCV-30, and histopathologic changes were,
analyzed at days 7, 21, 45, and 90 p.i. Micrographs show acute
inflammatory and degenerative changes in the myocardium at 7 days p.i.
(A), an inflammatory and fibrotic myocardial lesion at 21 days
p.i. (B), myocardial lymphocyte infiltration at 90 days p.i. (C), and
perivascular cuffing in the cerebral cortex at 90 days p.i. (D). Heart
and brain sections were embedded in paraffin, and 4-µm-thick sections
were stained with hematoxylin and eosin. Magnification, ×200 for
panels A through C and ×400 for panel D.
|
|

View larger version (10K):
[in this window]
[in a new window]
|
FIG. 2.
Scatter plot showing pathology scores of heart tissues
from EMCV-infected pigs. Five-week-old pigs were intraperitoneally
inoculated with 2.9 × 108 PFU of EMCV-30, and
histopathologic changes were analyzed at 3 (n = 4), 7 (n = 5), 21(n = 6), 45 (n = 5), and 90 (n = 5) days p.i. Each heart tissue
section was given a score between 0 (no pathology) and 4 (necrosis on
days 3 and 7, or fibrosis on days 21, 45, and 90) based on the extent
of pathology as described in Materials and Methods. Solid lines
represent the mean score at each time point (3 at day 3, 2.7 at day 7, 1.6 at day 21, 1.4 at day 45, and 1.2 at day 90 p.i.). The data
indicate that EMCV, causes acute damage to the heart tissue, but in
some pigs it can establish persistent infection.
|
|

View larger version (162K):
[in this window]
[in a new window]
|
FIG. 3.
EMCV-induced apoptosis in pig myocardium. Frozen
sections of the heart were immunostained to identify cells undergoing
apoptosis using the in situ end-labeling peroxidase-based detection
system. Extensive apoptosis (brown-stained cells indicated by arrows)
was observed at day 7 p.i., and fewer apoptotic cells were detectable
at days 45 and 90 p.i. Uninfected myocardial sections were
negative. Sections were lightly counterstained with hematoxylin.
Magnification, ×100.
|
|
Histopathologic changes in the brain included infiltration of
inflammatory cells in the meninges and perivascular cuffing
in the
cerebral cortex and hippocampi in 5 of 15 (33.3%) pigs
examined
between days 3 and 21 p.i. In addition, there was neuronal
degeneration in four (26.3%) and foci of gliosis in two (13.3%)
pigs.
In the chronic phase, perivascular cuffing was observed
in the cerebral
cortex, medulla, and cerebellum in 3 of 10 (30%)
pigs (Fig.
1D).
Spleens had mild lymphocytic hyperplasia at day
7 p.i. but no
histopathologic changes at any other time point.
There were no
pathologic changes detected in the liver, pancreas,
kidney, skeletal
muscle, or mesenteric lymph nodes. The presence
of pathologic changes
in the myocardium and brain in the chronic
stages of EMCV infection
suggested that viral persistence either
directly induced tissue damage
or stimulated immune effector functions
that caused tissue
damage.
Presence of EMCV antigens and RNA in pig myocardium 90 days
p.i.
EMCV persistence was analyzed using in situ hybridization and
nested RT-PCR on the heart, brain, liver, kidney, spleen, skeletal muscle, pancreas, and mesenteric lymph nodes. In situ hybridization localized EMCV RNA in heart, brain, spleen, kidney, and skeletal muscle
at days 3, 7, and 21 p.i., but in myocardium and brain only in the
chronic phase of the disease (Fig. 4A and
B). More importantly, EMCV antigens were localized in the myocardium
using anti-EMCV RNA polymerase 90 days after infection (Fig. 5C).
Hybridization and immunostaining performed on myocardial tissues from
uninfected control pigs were negative for viral RNA and antigens (data
not shown). RT-PCR analysis of tissues from pigs that died from acute cardiac failure at day 3 p.i. showed large amounts of viral RNA in
all tissues. Viral VP1 and VP2 RNA were easily demonstrated by gel
electrophoresis after primary PCR, whereas at other time points (days
7, 21, 45, and 90) nested PCR was required to produce visible
electrophoresis bands. This indicated a greater viral load in tissues
at the early stage of the disease (day 3 p.i.). At days 7 and
21 p.i., EMCV RNA was detected in heart and spleen tissues (7 of
10 pigs), whereas in the chronic stages of the disease (days 45 and
90 p.i.), EMCV RNA was most commonly detected in brain (7 of 10 pigs), heart (6 of 10 pigs), and skeletal
muscle (6 of 10 pigs) as shown in Table 1 and Fig.
5. Uninfected control pig tissues did not
generate PCR products. The observation that 12 of 16 hearts (75%) were
positive for EMCV RNA between days 21 and 90 p.i. reinforced
pathology data suggesting that the heart is the primary site of EMCV
persistence in pigs (Table 1).

View larger version (61K):
[in this window]
[in a new window]
|
FIG. 4.
Localization of EMCV RNA and antigens in the hearts and
brains of chronically EMCV-infected pigs. EMCV RNA was localized by in
situ hybridization using a 309-bp 35S-labeled VP2-specific
probe in the myocardium (A) and brain (B) of a pig infected for 90 days. Black grains (arrows) indicate viral RNA-positive cells. (C)
Demonstration of EMCV antigens (brown staining, indicated by arrows) in
the myocardium of a 90-day-infected pig by immunohistochemistry using a
monoclonal antibody specific for EMCV RNA polymerase.
Magnification, ×268 for panels A and B and ×134 for panel C.
|
|

View larger version (59K):
[in this window]
[in a new window]
|
FIG. 5.
Detection of EMCV RNA in pig tissues by RT-PCR.
Five-week-old pigs were intraperitoneally inoculated with 2.9 × 108 PFU of EMCV-30, and the brain, heart, kidney, liver,
spleen, and skeletal muscle were tested by nested RT-PCR for EMCV RNA
using VP1- or VP2-specific primer sets at days 7, 21, 45, and 90 p.i. (A) Agarose DNA gel showing RT-PCR products specific for VP1 (436 bp) and VP2 (390 bp) in the heart (lanes 2), liver (lanes 4), spleen
(lanes 5), and skeletal muscle (lanes 6) of a pig infected for 90 days.
The brain was positive with VP1 primers (lane 1) but negative with VP2
primers (lane not shown), whereas the kidney was negative with both VP1
and VP2 primers. (B) Presence of EMCV RNA in hearts of seronegative
commercial pigs. Hearts were obtained at the time of slaughter and
tested by nested RT-PCR. The gel shows that pig 67 was positive
for VP1 RNA whereas the rest of the pigs (animals 61 to 66 and 68 to
70) were negative. Two of the 100 pig hearts analyzed (from 10 different herds) were positive.
|
|
Pig tissues can transmit EMCV to immunocompromised animals.
To
determine the ability of infected pig tissues to transmit EMCV to a
susceptible host, homogenized pig myocardial tissues harvested 7, 21, 45, or 90 days p.i. were intraperitoneally inoculated into
recombination activation gene 2-deficient (RAG2
/
) mice.
RAG2
/
mice lack B or T lymphocytes and are susceptible
to acute viral infections. Myocardial tissues were homogenized to a
10% suspension in RPMI-1640 medium and passed through a
0.2-µm-pore-size filter. Mice were intraperitoneally injected with 1 µl of the homogenate and monitored for clinical signs of myocarditis
and encephalitis. As a positive control, RAG2
/
mice
were inoculated with 10 PFU of EMCV-30 per mouse. The
RAG2
/
mice inoculated with 10 PFU of EMCV-30
(n = 2) died 35 to 38 days later, whereas mice
inoculated with myocardial homogenate from day 7-infected pigs
(n = 4) died 27 to 54 days after inoculation as a
result of EMCV-induced disease. RAG2
/
mice inoculated
with homogenate from pigs infected for 21 (n = 4), 45 (n = 4), or 90 (n = 4) days showed no
clinical signs of EMCV disease for 60 days.
EMCV RNA can be detected in seronegative pigs.
The
experimentally infected pigs rapidly developed EMCV-specific
neutralizing IgGs within 7 days (Fig.
6A), reaching peak levels by day 21 p.i. before dropping to low levels by day 45 p.i. (Fig. 6B). All
sera from pigs infected for 7, 21, 45, or 90 days neutralized EMCV. We
envisioned that persistent EMCV may escape detection by routine
serological methods such as virus neutralization and ELISA. To
investigate this possibility, tissues from 10 pig herds obtained from a
farm that has been EMCV free were examined. Ten pig hearts and serum
samples from the same pigs were analyzed for each herd. Sera were
tested for EMCV-specific IgG and neutralizing antibodies. All 100 pigs
were negative by virus neutralization (no neutralization at a 1:16
dilution) and ELISA (Fig. 6C). However, EMCV RNA was reproducibly
demonstrated by RT-PCR in 2 of the 100 heart tissues tested (Fig. 5B),
both of which had no detectable EMCV antibodies by virus neutralization (at a 1:16 dilution) or ELISA (absorbance reading below 0.2). To
eliminate the possibility of contamination, PCR tests were conducted in
a room dedicated to the test, and each test included positive- and
negative-control samples.

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 6.
Detection of EMCV-specific IgG in sera from
experimentally infected and commercial pigs. EMCV-specific IgGs were
determined by ELISA. (A) Virus-specific IgG levels in sera of pigs
infected for 7, 21, 45, and 90 days. Data are means (± standard
errors) of A405 readings from four to five serum
samples at each time point, performed at serum dilutions between 1:125
and 1:128,000. (B) Profile of virus-specific IgG levels during acute
(day 7 to 21) and chronic (day 45 to 90) infection determined at a
1:500 serum dilution, showing that antibody levels peaked at day
21 p.i. before decreasing to low levels at days 45 and 90 p.i. (C) Analysis of EMCV-specific IgGs in sera from 10 commercial pig
herds obtained from an EMCV-free farm over a 10-month period. Each herd
is represented by the mean (± standard error)
A405 reading of serum samples from 10 pigs. Sera
from pigs experimentally infected with EMCV for 21 days were used as a
positive control.
|
|
EMCV can infect human myocardial cells.
The ability of porcine
EMCV to infect human cells was assessed by inoculating primary human
cardiomyocytes, renal epithelial cells, bone marrow progenitor cells,
aortic endothelial cells, peripheral blood mononuclear cells, and
hepatocytes with 3 to 5 PFU per cell of EMCV-30. Cells were harvested 7 and 16 h after inoculation and were subjected to
immunohistochemistry and in situ hybridization to localize viral
antigens and RNA, respectively. Of importance was the immunostaining
using a monoclonal antibody specific for EMCV RNA polymerase (3D
protein), because the polymerase is detected only during productive
virus infection in susceptible cells. Human cardiomyocytes demonstrated
high immunoreactivity with anti-EMCV polymerase antibody (Fig.
7B), whereas uninfected cells were
negative (Fig. 7A). Ninety-five percent of the EMCV-inoculated cardiomyocytes were positive for viral polymerase, and the reactivity was always in the cytoplasm (Fig 7B), confirming the cytoplasmic restriction of EMCV replication. Productive infection of the
cardiomycytes was further confirmed by the large amount of viral RNA
localized in inoculated cells (Fig. 7D) compared to uninfected
cardiomyocytes hybridized for the virus (Fig. 7C). More than 95% of
the cardiomyocytes infected for 16 h underwent cytolysis, and the
remaining viable cells (5%) were positive for EMCV antigens and RNA.
Hepatocytes, renal cells, aortic endothelial cells, bone marrow
progenitor cells, peripheral blood mononuclear cells, and neuroblastoma
cells were negative for EMCV polymerase antigens. These results
indicated that human cardiomyocytes are susceptible to porcine EMCV
infection.

View larger version (142K):
[in this window]
[in a new window]
|
FIG. 7.
EMCV antigens and RNA in primary human myocardial cells.
Primary human cardiomyocytes obtained from Clonetics were inoculated
with 3 to 5 PFU of EMCV-30 per cell, for 7 h. Cells were harvested
and immunostained using a anti-EMCV RNA polymerase (3D protein)
monoclonal antibody. Infected human cardiomyocytes were positive, as
shown by the brown staining in the cytoplasm (B), whereas uninfected
cells were negative (A). In addition, in situ hybridization using a
309-bp 35S-labeled probe specific for the VP2 gene of EMCV
was used to localize viral RNA in the infected cells. Large amounts of
viral RNA were observed in human cardiomyocytes (black grains) infected
with EMCV (D), whereas uninfected cells hybridized with the VP2 cDNA
probe were negative (C). Cells were lightly counterstained with
hematoxylin. Magnification, ×400.
|
|
To determine whether porcine EMCV can productively infect human
cardiomyocytes, confluent primary human cardiomyocytes were
grown in
12-well tissue culture plates and inoculated with 10
PFU of EMCV-30 per
cell for 1, 2, 4, 6, 8, or 16 h before harvesting.
Infected cells
were washed to remove unattached virus, and four
wells were harvested
at each time point using a cell scraper.
The cells were freeze-thawed
and sonicated to release intracellular
virus and were centrifuged to
remove cellular debris, and serial
10-fold dilutions were added to a
confluent HeLa cell monolayer
for a plaque assay as described
previously for TMEV (
25). The
results show a typical
picornaviral growth curve with a 4-h lag
(latent or eclipse) phase
followed by a 2-h exponential (log)
phase characterized by production
of 100 to 1,000 PFU of virus
per cell (Fig.
8). The EMCV growth curve shows that
human cardiomyocytes
can be efficiently and productively infected by
porcine EMCV.

View larger version (11K):
[in this window]
[in a new window]
|
FIG. 8.
Growth curve demonstrating productive infection of
primary human cardiomyocytes by porcine EMCV. Confluent primary human
cardiomyocytes in 12-well tissue culture plates were inoculated with 10 PFU of EMCV-30 per cell for 1, 2, 4, 6, 8, or 16 h before harvesting.
Infected cells were washed to remove unattached virus, and four wells
were harvested at each time point for a plaque assay (3.1 × 105 cells/well). Cells were freeze-thawed and sonicated to
release intracellular virus and clarified by centrifugation, and serial
10-fold dilutions were added to confluent HeLa cells for plaque
development. Results are expressed as the mean (± standard error)
number of plaques per 6.2 × 105 cells (from two
wells) of four samples per time point. They show a 4-h lag phase
followed by a 2-h exponential phase characterized by rapid production
of infectious EMCV particles. The limit of detection for the test was 2 PFU per 6.2 × 105 cells.
|
|
 |
DISCUSSION |
Previous studies have suggested that EMCV can be detected beyond
the acute myocarditis and encephalitis phase of the disease in pig
tissues (2, 19). Piglets infected with EMCV for 23 days
and subsequently treated with an immunosuppressive drug developed myocardial pathologic and enzymatic abnormalities and transmitted the
virus to susceptible contact pigs (2). However, a
comprehensive study to determine the duration, location in tissues, and
form of porcine EMCV persistence in pig tissues had not been performed. The importance of such an undertaking, and of determining the potential
of persistent porcine EMCV to infect humans, has been rekindled by
advances in pig-to-human xenotransplantation. Our studies demonstrate,
for the first time, EMCV-induced pathologic changes (lymphocyte
infiltration, myocardial degeneration, and apoptosis), and EMCV
antigens and RNA in porcine myocardium for as long as 90 days after
infection, suggesting the presence of infectious viral particles and/or
active inflammatory processes in the chronic stages of infection. In
addition, EMCV RNA, but not pathologic changes, was detected in the
spleen, kidney, and skeletal muscles in the chronic stages (days 45 and
90 p.i.) of infection. Clearly, EMCV induced the most extensive
pathologic changes in the myocardium early in the disease process
(within 7 days), and approximately 40% of these pigs recovered with no detectable myocardial damage by day 21 after infection, as shown in
Fig. 2. However, more than 60% of the pigs had myocardial pathologic changes, some of them severe (pathology scores of 3 and 4), in the
chronic phase of the disease. Given that our attempts to isolate infectious virus in the chronic phase of the disease were unsuccessful, one may conclude that the persistent viral products detected (antigens and RNA) were not products of an infectious virus present in these tissues. However, it should be noted that both the viral antigens and
pathologic changes, including lymphocyte infiltration and apoptosis,
were detected in myocardial cells throughout the chronic disease. Most
likely, the inability to detect infectious virus was due to a
combination of insensitivity of the techniques used (plaque assay and
mortality in RAG2-deficient mice), and inadequate sampling
because only small portions of the pig heart could be processed for
virus isolation.
We also investigated the hypothesis that persistent EMCV in pigs may
escape detection by the existing serologic methods to pose a risk in
xenotransplantation. In agreement with this hypothesis, EMCV RNA was
demonstrated in 2 out of 100 pig hearts obtained from commercial pigs
at the time of slaughter. These findings are important because the
success of xenotransplantation is predicated on efficient and
error-free screening of donor animal tissues for potential infectious
agents. The findings point to a need to develop a rapid bedside RT-PCR
test for screening pig tissues harvested for transplantation against
zoonotic porcine virus genes.
EMCV-30 productively infected primary human cardiomyocytes, indicating
that persistent EMCV in pig tissues can pose a risk to humans. More
than 95% of the EMCV-infected cardiomyocytes underwent cytolysis
between 7 and 16 h after inoculation, whereas the remaining 5% of
viable cells still supported EMCV replication. Combined with the
pathologic findings for the infected pigs, these data indicate that
EMCV is capable of inducing cytodestructive changes in both human and
pig myocardial cells. The demonstration of EMCV persistence and
pathologic changes in chronic infection, and the ability of the virus
to productively infect human cells, makes EMCV an ideal model of
characterizing the risk of transplanting virus-infected pig tissues
into humans. A recent study has shown showed that the presence of
picornavirus, adenovirus, parvovirus, and herpesvirus genomes within
transplanted hearts results in increased graft loss in children
(33). Cardiac transplants comprise a large portion of
organ replacement procedures performed in the United States, and many
human patients die while waiting for donors. Mechanical heart devices,
used mostly for bridge-to-transplant therapy, have not been successful
for long-term use, leaving animals as an important alternative source
of healthy hearts (1, 8, 20). Identifying potential
zoonotic infectious viruses and characterizing the risk they pose to
human transplant recipients is important in advancing
xenotransplantation research.
 |
ACKNOWLEDGMENTS |
This work was supported by National Institutes of Health grant
HL04369-01.
We thank HanSoo Joo of the University of Minnesota for providing
EMCV-30 and Stephen Strom of the University of Pittsburgh for providing
human hepatocytes. We also thank Kjerstin Cameron, Zhengguo Xiao,
Xuexian Zhang, and Cristina Marques for technical assistance.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Veterinary Pathobiology, University of Minnesota, 1971 Commonwealth
Ave., St. Paul, MN 55108. Phone: (612) 625-2719. Fax: (612) 625-5203. E-mail: Njeng001{at}tc.umn.edu.
 |
REFERENCES |
| 1.
|
Acker, M. A.
2001.
Mechanical circulatory support for patients with acute-fulminant myocarditis.
Ann. Thorac. Surg.
71:S73-S76[Abstract/Free Full Text].
|
| 2.
|
Billinis, C.,
E. Paschaleri-Papadopoulou,
V. Psychas,
J. Vlemmas,
S. Leontides,
M. Koumbati,
S. C. Kyriakis, and O. Papadopoulos.
1999.
Persistence of encephalomyocarditis virus (EMCV) infection in piglets.
Vet. Microbiol.
70:171-177[CrossRef][Medline].
|
| 3.
|
Blanchard, J. L.,
K. F. Soike, and G. B. Baskin.
1987.
Encephalomyocarditis virus infection in African green and squirrel monkeys: comparison of pathological effects.
Lab. Anim. Sci.
37:635-639[Medline].
|
| 4.
|
Cerutis, D. R.,
R. H. Bruner,
D. C. Thomas, and D. J. Giron.
1989.
Tropism and histopathology of the D, B, K, and MM variants of encephalomyocarditis virus.
J. Med. Virol.
29:63-69[Medline].
|
| 5.
|
Craighead, J. E.,
P. H. Peralata,
T. G. Murnane, and A. Shelokov.
1963.
Oral infection of swine with encephalomyocarditis virus.
J. Infect. Dis.
112:205-212[Medline].
|
| 6.
|
Duke, G. M.,
M. A. Hoffman, and A. C. Palmenberg.
1992.
Sequence and structural elements that contribute to efficient encephalomyocarditis viral RNA translation.
J. Virol.
66:1602-1609[Abstract/Free Full Text].
|
| 7.
|
Duque, H., and A. C. Palmenberg.
1996.
Epitope mapping of monoclonal antibodies raised to recombinant Mengo 3D polymerase.
Virus Genes
13:159-168[CrossRef][Medline].
|
| 8.
|
El-Banayosy, A.,
R. Korfer,
L. Arusoglu,
L. Kizner,
M. Morshuis,
H. Milting,
G. Tenderich,
O. Fey, and K. Minami.
2001.
Device and patient management in a bridge-to-transplant setting.
Ann. Thorac. Surg.
71:S98-S102[Abstract/Free Full Text].
|
| 9.
|
Gainer, J. H.
1967.
Encephalomyocarditis virus infections in Florida.
J. Am. Vet. Med. Assoc.
151:421-424[Medline].
|
| 10.
|
Gajdusek, C.
1955.
Encephalomyocarditis infection in childhood.
Pediatrics
16:819[Abstract/Free Full Text].
|
| 11.
|
Grobler, D. G.,
J. P. Raath,
L. E. O. Braack,
D. F. Keet,
G. H. Gerdes,
B. J. H. Barnard,
N. P. J. Kriek,
J. Jardine, and R. Swanepoel.
1995.
An outbreak of encephalomyocarditis-virus infection in free-ranging African elephants in the Kruger national park.
Onderstepoort J. Vet. Res.
62:97-108[Medline].
|
| 12.
|
Hahn, H., and A. C. Palmenberg.
1995.
Encephalomyocarditis viruses with poly(C) tracts are more virulent then their mengovirus counterparts.
J. Virol.
69:2697-2699[Abstract].
|
| 13.
|
Harvey, J.,
W. Iverson,
P. McArdle,
C. McGovern,
M. Perry, and W. Tente.
1997.
An assessment of several alternative species as donors for xenotransplantation. A White Paper response to PHS Guidelines on Infectious Disease Issues in Xenotransplantation.
Biotechnology Industry Organization, Washington, D.C.
|
| 14.
|
Hubbard, G. B.,
K. F. Soike,
T. M. Butler,
K. D. Carey,
H. Davis,
W. I. Butcher, and C. J. Gauntt.
1992.
An encephalomyocarditis virus epizootic in a baboon colony.
Lab. Anim. Sci.
42:233-239[Medline].
|
| 15.
|
Joo, H. S.
1999.
Encephalomyocarditis virus, p. 139-144.
In
B. E. Straw, S. D'Allaire, W. L. Mengeling, and D. J. Taylor (ed.), Diseases of swine, 8th ed. Iowa State University Press, Ames, Iowa.
|
| 16.
|
Kim, H. S.,
W. T. Christianson, and H. S. Joo.
1991.
Characterization of encephalomyocarditis virus isolated from aborted swine fetuses.
Am. J. Vet. Res.
52:1649-1652[Medline].
|
| 17.
|
Kirkland, P. D.,
A. B. Gleeson,
R. A. Hawkes,
H. M. Naim, and C. R. Broughton.
1989.
Human infection with encephalomyocarditis virus in New South Wales.
Med. J. Aust.
151:176-177.
|
| 18.
|
Knowles, N. J.,
N. D. Dickinson,
G. Wilson,
E. Carra,
E. Brocchi, and F. De Simone.
1998.
Molecular analysis of encephalomyelitis viruses isolated from pigs and rodents in Italy.
Virus Res.
57:53-62[CrossRef][Medline].
|
| 19.
|
Koenen, F.,
K. De Clercq,
J. Lefebvre, and R. Strobbe.
1994.
Reproductive failure in sows following experimental infection with a Belgian EMCV isolate.
Vet. Microbiol.
39:111-116[CrossRef][Medline].
|
| 20.
|
Kozlowski, T.,
A. Shimizu,
D. Lambrigts,
K. Yamada,
Y. Fuchimoto,
R. Glaser,
R. Monroy,
Y. Xu,
M. Awwad,
R. B. Colvin,
A. B. Cosimi,
S. C. Robson,
J. Fishman,
T. R. Spitzer,
D. K. Cooper, and D. H. Sachs.
1999.
Porcine kidney and heart transplantation in baboons undergoing a tolerance induction regimen and antibody adsorption.
Transplantation
67:18-30[CrossRef][Medline].
|
| 21.
|
Kyu, B.,
A. Matsumori,
Y. Sato,
I. Okada,
N. M. Chapman, and S. Tracy.
1992.
Cardiac persistence of cardioviral RNA detected by polymerase chain reaction in a murine model of dilated cardiomyopathy.
Circulation
86:522-530[Abstract/Free Full Text].
|
| 22.
|
Lipton, H. L.,
J. Kratochvil,
P. Seth, and M. C. Dal Canto.
1984.
Theiler's virus antigens detected in mouse spinal cord 2 1/2 years after infection.
Neurology
34:1117-1119[Abstract/Free Full Text].
|
| 23.
|
Low, W. C.,
J. K. Daniloff,
R. P. Bodony, and J. Wells.
1985.
Cross-species transplants of cholinergic neurons and the recovery of function, p. 575-584.
In
A. Bjorkmund, and U. Stenevi (ed.), Neural grafting in the mammalian CNS. Elsevier Science Publications, Amsterdam, The Netherlands.
|
| 24.
|
Murnane, T. G.
1981.
Encephalomyocarditis, p. 137-147.
In
G. W. Beran (ed.), CRC handbook series in zoonoses, section B, vol. 2. Viral zoonoses. CRC Press, Boca Raton, Fla.
|
| 25.
|
Njenga, M. K.,
K. Asakura,
S. F. Hunter,
P. Wettstein,
L. R. Pease, and M. Rodriguez.
1997.
The immune system preferentially clears Theiler's virus from the gray matter of the central nervous system.
J. Virol.
71:8592-8601[Abstract].
|
| 26.
|
Njenga, M. K.,
K. D. Pavelko,
J. Baisch,
X. Lin,
C. David,
J. Leibowitz, and M. Rodriguez.
1996.
Theiler's virus persistence and demyelination in major histocompatibility complex class II-deficient mice.
J. Virol.
70:1729-1737[Abstract].
|
| 27.
|
Pakzaban, P., and O. Isacson.
1994.
Neural xenotransplantation: reconstruction of neuronal circuitry across species barriers.
Neuroscience
62:989-1001[CrossRef][Medline].
|
| 28.
|
Petruccelli, M. A.,
K. Hirasawa,
M. Takeda,
S. Itagaki, and K. Doi.
1991.
Cardiac and pancreatic lesions in guinea pigs infected with encephalomyocarditis (EMC) virus.
Histol. Histopathol.
6:167-170[Medline].
|
| 29.
|
Quinn, N.
1990.
The clinical application of cell grafting techniques in patients with Parkinson's disease.
Prog. Brain Res.
82:619-625[Medline].
|
| 30.
|
Reddacliff, L. A.,
P. D. Kirkland,
W. J. Hartley, and R. L. Reece.
1997.
Encephalomyocarditis virus infections in an Australian zoo.
J. Zoo Wild1. Med.
28:153-157[Medline].
|
| 31.
|
Seaman, J. T.,
J. G. Boulton, and M. J. Carrigan.
1986.
Encephalomyocarditis virus disease of pigs associated with a plague of rodents.
Aust. Vet. J.
63:292-294[Medline].
|
| 32.
|
Secchi, A.,
C. Socci,
P. Maffi,
M. V. Taglietti,
L. Falqui,
F. Bertuzzi,
P. De Nittis,
L. Piementi,
L. Scopsi,
V. Di Carlo, and G. Pozza.
1997.
Islet transplantation in IDDM patients.
Diabetologia
40:225-231[CrossRef][Medline].
|
| 33.
|
Shirali, G. S.,
J. Ni,
R. E. Chinnock,
J. K. Johnston,
G. L. Rosenthal,
N. E. Bowles, and J. A. Towbin.
2001.
Association of viral genome with graft loss in children after cardiac transplantation.
N. Engl. J. Med.
344:1498-1503[Abstract/Free Full Text].
|
| 34.
|
Soderlund, J.,
L. Wennberg,
E. Castanos-Velez,
P. Biberfeld,
S. Zhu,
A. Tibell,
C. G. Groth, and O. Korsgren.
1999.
Fetal porcine islet-like cell clusters transplanted to cynomolgus monkey: an immunohistochemical study.
Transplantation
67:784-891[CrossRef][Medline].
|
| 35.
|
Spadrow, P. B., and Y. S. Chung.
1970.
Hemagglutination-inhibition antibodies to encephalomyocarditis virus in Queensland cattle.
Aust. Vet. J.
46:126-128[Medline].
|
| 36.
|
Tesh, R. B.
1978.
The prevalence of encephalomycarditis virus neutralizing antibodies among various human populations.
Am. J. Trop. Med. Hyg.
27:144-149.
|
| 37.
|
Thou, J.,
I. Date,
K. Sakai,
Y. Yoshimoto,
T. Furuta,
S. Asari, and T. Ohmoto.
1993.
Suppression of immunorejection against rat fetal dopaminergic neurons in a mouse brain by 15-deoxyspergualin.
Brain Res.
621:155-160[CrossRef][Medline].
|
| 38.
|
Verlinde, J. D., and H. E. Van Tangeren.
1953.
Human infections with viruses of the Columbia-SK group.
Arch. Ges. Virusforsch.
5:217-230.
|
| 39.
|
Warren, J.
1965.
Encephalomyelitis viruses, p. 562-568.
In
F. L. Horsfall, Jr., and I. Tamm (ed.), Viral and rickettsial infections of man, 4th ed. J. B. Lippincott Company, Philadelphia, Pa.
|
| 40.
|
Wee, L.,
P. Liu,
L. Penn,
J. W. Butany,
P. R. McLaughlin,
M. J. Sole, and C. C. Liew.
1992.
Persistence of viral genome into late stages of murine myocarditis detected by polymerase chain reaction.
Circulation
86:1605-1614[Abstract/Free Full Text].
|
| 41.
|
Wells, S. K., and A. E. Gutter.
1989.
Encephalomyocarditis virus: epizootic in a zoological collection.
J. Zoo Wild1. Med.
20:291-296.
|
| 42.
|
Zimmerman, J. J.,
H. T. Hill,
G. W. Beran, and M. C. Meetz.
1990.
Serological diagnosis of encephalomyocarditis virus infection in swine by the microtiter serum neutralization test.
J. Vet. Diagn. Investig.
4:347-350.
|
| 43.
|
Zimmerman, J. J.,
R. E. Hill,
K. E. Smith,
B. L. Kneeland,
K. B. Platt,
H. T. Hill,
G. W. Beran,
W.R. Clark, and L. D. Miller.
1994.
Encephalomyocarditis virus infection in raccoons (Procyon lotor).
J. Zoo Wild1. Med.
25:233-239.
|
Journal of Virology, December 2001, p. 11621-11629, Vol. 75, No. 23
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.23.11621-11629.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Romanova, L. I., Lidsky, P. V., Kolesnikova, M. S., Fominykh, K. V., Gmyl, A. P., Sheval, E. V., Hato, S. V., van Kuppeveld, F. J. M., Agol, V. I.
(2009). Antiapoptotic Activity of the Cardiovirus Leader Protein, a Viral "Security" Protein. J. Virol.
83: 7273-7284
[Abstract]
[Full Text]
-
Schwab, I. R., Johnson, N. T., Harkin, D. G.
(2006). Inherent Risks Associated With Manufacture of Bioengineered Ocular Surface Tissue. Arch Ophthalmol
124: 1734-1740
[Abstract]
[Full Text]
-
LaRue, R., Myers, S., Brewer, L., Shaw, D. P., Brown, C., Seal, B. S., Njenga, M. K.
(2003). A Wild-Type Porcine Encephalomyocarditis Virus Containing a Short Poly(C) Tract Is Pathogenic to Mice, Pigs, and Cynomolgus Macaques. J. Virol.
77: 9136-9146
[Abstract]
[Full Text]